NCT07523737 2026-04-15
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Beijing Tongren Hospital
Phase 2 Recruiting
Clinical Trials
6 trialsNCT05389423 2026-02-19
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT07257510 2025-12-02
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Peking University Third Hospital
Phase NA Recruiting
NCT05348213 2024-10-23
R-ICE+X
Ruijin Hospital
Phase 2 Recruiting
NCT05809180 2023-04-20
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
The First Affiliated Hospital of Soochow University
Phase NA Recruiting